Literature DB >> 19164596

Antigen mRNA-transfected, allogeneic fibroblasts loaded with NKT-cell ligand confer antitumor immunity.

Shin-ichiro Fujii1, Akira Goto, Kanako Shimizu.   

Abstract

The maturation of dendritic cells (DCs) in situ by danger signals plays a central role in linking innate and adaptive immunity. We previously demonstrated that the activation of invariant natural killer T (iNKT) cells by administration of alpha-galactosylceramide (alpha-GalCer)-loaded tumor cells can act as a cellular adjuvant through the DC maturation. In the current study, we used allogeneic fibroblasts loaded with alpha-GalCer and transfected with antigen-encoding mRNA, thus combining the adjuvant effects of iNKT-cell activation with delivery of antigen to DCs in vivo. We found that these cells produce antigen protein and activate NK and iNKT cells. When injected into major histocompatibility complex (MHC)-mismatched mice, they elicited antigen-specific T-cell responses and provided tumor protection, suggesting that these immune responses depend on host DCs. In addition, antigen-expressing fibroblasts loaded with alpha-GalCer lead to a more potent T-cell response than those expressing NK cell ligands. Thus, glycolipid-loaded, mRNA-transfected allogeneic fibroblasts act as cellular vectors to provide iNKT-cell activation, leading to DC maturation and T-cell immunity. By harnessing the innate immune system and generating an adaptive immune response to a variety of antigens, this unique tool could prove clinically beneficial in the development of immunotherapies against malignant and infectious diseases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19164596     DOI: 10.1182/blood-2008-08-176446

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  16 in total

Review 1.  Immunotherapeutic strategies targeting natural killer T cell responses in cancer.

Authors:  Susannah C Shissler; Dominique R Bollino; Irina V Tiper; Joshua P Bates; Roshanak Derakhshandeh; Tonya J Webb
Journal:  Immunogenetics       Date:  2016-07-08       Impact factor: 2.846

2.  6″-Modifed α-GalCer-peptide conjugate vaccine candidates protect against liver-stage malaria.

Authors:  Michael A Meijlink; Yu Cheng Chua; Susanna T S Chan; Regan J Anderson; Matthew W Rosenberg; Anton Cozijnsen; Vanessa Mollard; Geoffrey I McFadden; Sarah L Draper; Lauren E Holz; Ian F Hermans; William R Heath; Gavin F Painter; Benjamin J Compton
Journal:  RSC Chem Biol       Date:  2022-03-02

Review 3.  Enhancement of Adjuvant Functions of Natural Killer T Cells Using Nanovector Delivery Systems: Application in Anticancer Immune Therapy.

Authors:  Reem Ghinnagow; Luis Javier Cruz; Elodie Macho-Fernandez; Christelle Faveeuw; François Trottein
Journal:  Front Immunol       Date:  2017-07-27       Impact factor: 7.561

Review 4.  Exploiting Antitumor Immunotherapeutic Novel Strategies by Deciphering the Cross Talk between Invariant NKT Cells and Dendritic Cells.

Authors:  Shin-Ichiro Fujii; Kanako Shimizu
Journal:  Front Immunol       Date:  2017-07-31       Impact factor: 7.561

Review 5.  Reciprocal Crosstalk between Dendritic Cells and Natural Killer T Cells: Mechanisms and Therapeutic Potential.

Authors:  Christian W Keller; Stefan Freigang; Jan D Lünemann
Journal:  Front Immunol       Date:  2017-05-24       Impact factor: 7.561

6.  In vivo dendritic cell targeting cellular vaccine induces CD4+ Tfh cell-dependent antibody against influenza virus.

Authors:  Satoru Yamasaki; Kanako Shimizu; Kohei Kometani; Maki Sakurai; Masami Kawamura; Shin-Ichiro Fujii
Journal:  Sci Rep       Date:  2016-10-14       Impact factor: 4.379

7.  Immunotherapy with artificial adjuvant vector cells: Harnessing both arms of the immune response.

Authors:  Shin-Ichiro Fujii; Kanako Shimizu
Journal:  Oncoimmunology       Date:  2013-04-01       Impact factor: 8.110

Review 8.  NKT cells as an ideal anti-tumor immunotherapeutic.

Authors:  Shin-Ichiro Fujii; Kanako Shimizu; Yoshitaka Okamoto; Naoki Kunii; Toshinori Nakayama; Shinichiro Motohashi; Masaru Taniguchi
Journal:  Front Immunol       Date:  2013-12-02       Impact factor: 7.561

9.  Natural Killer T Cell-Targeted Immunotherapy Mediating Long-term Memory Responses and Strong Antitumor Activity.

Authors:  Nyambayar Dashtsoodol; Tomokuni Shigeura; Takuya Tashiro; Minako Aihara; Toshihiro Chikanishi; Hiromi Okada; Keigo Hanada; Hirokazu Sano; Akihiko Kurogi; Masaru Taniguchi
Journal:  Front Immunol       Date:  2017-09-25       Impact factor: 7.561

Review 10.  Dead cell phagocytosis and innate immune checkpoint.

Authors:  Kyoung Wan Yoon
Journal:  BMB Rep       Date:  2017-10       Impact factor: 4.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.